8-K: Corbus Pharmaceuticals Reports Q3 2024 Results, Advances Pipeline

Corbus Pharmaceuticals announced its third quarter 2024 financial results and provided updates on its clinical programs, including the completion of enrollment for the dose escalation phase of its CRB-701 trial and the expected commencement of a Phase 1 trial for CRB-913 in Q1 2025.

Summary

• Corbus Pharmaceuticals reported a net loss of $13.8 million, or $1.15 per diluted share, for the quarter ended September 30, 2024.
• This compares to a net loss of $10.1 million, or $2.27 per diluted share, for the same period in 2023.
• Operating expenses increased to $15.5 million, up from $9.5 million in the prior year, primarily due to increased clinical trial costs for CRB-701 and IND-enabling studies for CRB-913.
• The company had $159.4 million in cash, cash equivalents, and investments as of September 30, 2024, which is expected to fund operations through Q3 2027.
• Corbus completed enrollment of the dose escalation part of the Phase 1 clinical trial for CRB-701, with first data expected in Q1 2025.
• Pre-clinical data for CRB-913 was presented at Obesity Week 2024, and the Phase 1 trial is expected to commence in Q1 2025.
• The company also expects to dose the first patient in a Phase 1 study for CRB-601 in Q4 2024.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the company's progress in its clinical programs, strong cash position, and promising pre-clinical data. However, the net loss and increasing operating expenses temper the overall sentiment.

Positives

• The company has a strong cash position of $159.4 million, which is expected to fund operations through Q3 2027.
• Enrollment is complete for the dose escalation phase of the CRB-701 trial.
• Pre-clinical data for CRB-913 shows promising weight loss results in mice.
• The company is advancing multiple clinical programs with expected trial initiations in the near term.
• The company has paid off its loan of $11.8 million.

Negatives

• The company reported a net loss of $13.8 million for the quarter ended September 30, 2024.
• Operating expenses increased by $6.0 million compared to the same period in the prior year.
• The company is still in the clinical trial phase and has no products on the market.

Risks

• Clinical trial results may not be positive, which could impact the company's valuation.
• The company is dependent on raising additional capital in the future.
• There are risks associated with the development of new drugs, including regulatory hurdles and competition.
• The company's operating expenses are increasing, which could impact its profitability.

Future Outlook

The company expects to report first data from the CRB-701 U.S. bridging study in Q1 2025, commence a Phase 1 trial for CRB-913 in Q1 2025, and dose the first patient in a Phase 1 study for CRB-601 in Q4 2024. The company's cash is expected to fund operations through Q3 2027.

Management Comments

• We continue to make steady and significant progress across our pipeline, said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
• We expect to report the first data from the CRB-701 U.S. bridging study in Q1 2025.
• We are also pleased with the continued development of CRB-913, our highly peripherally restricted CB1 inverse agonist for the treatment of obesity.

Industry Context

The company is operating in the competitive oncology and obesity therapeutics market, with a focus on developing novel treatments. The company's Nectin-4 targeting ADC, CRB-701, is positioned to compete with existing treatments like PADCEV, while CRB-913 aims to address the growing obesity market. The company is also developing CRB-601, an anti-v8 monoclonal antibody, which targets the tumor microenvironment.

Comparison to Industry Standards

• The company's CRB-701 is being developed as a next-generation Nectin-4 ADC, aiming to improve upon the safety and efficacy profile of existing drugs like PADCEV. PADCEV has shown a 47% rate of serious adverse events, 61% dose interruptions, 34% dose reductions and 17% dose discontinuations, while CRB-701 has shown no dose limiting toxicities up to 4.5mg/Kg.
• CRB-913 is a peripherally restricted CB1 inverse agonist, designed to avoid the central nervous system side effects associated with earlier generation CB1 inhibitors like Rimonabant. Rimonabant had a 5.7% placebo-adjusted weight loss, while CRB-913 has shown up to 38% weight loss in diet-induced obese mice.
• Tivdak, a competitor in the cervical cancer space, has shown a 17.8% ORR vs 5.2% for chemotherapy, while CRB-701 has shown a 43% ORR in cervical cancer at doses of 1.2mg/Kg.
• Mabwell's 9MW-2821, another Nectin-4 ADC, has shown a 70% grade 3 AE rate, while CRB-701 has shown a 16% grade 3 AE rate.

Stakeholder Impact

• Shareholders will be impacted by the financial results and the progress of the clinical programs.
• Employees will be impacted by the company's financial performance and the progress of the clinical programs.
• Patients may benefit from the development of new treatments for cancer and obesity.
• Creditors will be impacted by the company's financial performance.

Next Steps

• Report first data from the CRB-701 U.S. bridging study in Q1 2025.
• Commence Phase 1 trial for CRB-913 in Q1 2025.
• Dose the first patient in a Phase 1 study for CRB-601 in Q4 2024.

Key Dates

Keywords

CRB-701, CRB-913, CRB-601, Nectin-4, ADC, CB1 inverse agonist, obesity, oncology, clinical trial, antibody, TGF, monoclonal antibody